Get the Stockscreener App
21.33
0.70%
-0.17
Immunome Inc stock is traded at $21.33, with a volume of 513.46K.
It is down -0.70% in the last 24 hours and down -17.47% over the past month.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
See More
Previous Close:
$21.50
Open:
$21.59
24h Volume:
513.46K
Relative Volume:
0.26
Market Cap:
$2.36B
Revenue:
$12.59M
Net Income/Loss:
$-212.39M
P/E Ratio:
-6.9134
EPS:
-3.0853
Net Cash Flow:
$-185.92M
1W Performance:
-3.66%
1M Performance:
-17.47%
6M Performance:
+107.28%
1Y Performance:
+124.26%
1-Day Range:
$21.22
$22.52
1-Week Range:
$21.22
$23.10
52-Week Range:
$5.1501
$27.65
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
21.35 | 2.37B | 12.59M | -212.39M | -185.92M | -3.0853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.92 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.28 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
831.02 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.67 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
366.49 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Initiated | H.C. Wainwright | Buy |
| Dec-01-25 | Initiated | Truist | Buy |
| Sep-22-25 | Initiated | Goldman | Buy |
| Sep-05-25 | Initiated | Craig Hallum | Buy |
| Apr-02-25 | Initiated | Lake Street | Buy |
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
Immunome to Present at Upcoming Investor Conferences - The Joplin Globe
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% - Yahoo Finance
Risk Analysis: Is Immunome Inc part of any ETF2025 Year in Review & Technical Pattern Based Signals - baoquankhu1.vn
Immunome, Inc. $IMNM Shares Acquired by NEOS Investment Management LLC - MarketBeat
Market Fear: Can Immunome Inc be the next market leaderShort Setup & Weekly Breakout Watchlists - baoquankhu1.vn
Is Immunome, Inc. (IMNM) the best booming stock to buy right now? - MSN
Brokers Issue Forecasts for Immunome FY2025 Earnings - MarketBeat
Trading Systems Reacting to (IMNM) Volatility - Stock Traders Daily
Immunome CEO Touts Phase 3 Desmoid Win, Near-Term FDA NDA Plan and Early IM-1021 ADC Responses - MarketBeat
Immunome (NASDAQ:IMNM) Stock Rating Upgraded by HC Wainwright - MarketBeat
Institutional investors in Immunome, Inc. (NASDAQ:IMNM) see US$269m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
H.C. Wainwright Coverage Puts Immunome Oncology Pipeline And Execution In Focus - Sahm
H.C. Wainwright initiates coverage on Immunome stock with Buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright initiates coverage on Immunome stock with Buy rating - Investing.com Nigeria
How do insiders feel about Immunome Inc.Market Growth Summary & Daily Stock Trend Reports - mfd.ru
HC Wainwright Initiates Immunome at Buy With $40 Price Target - marketscreener.com
Immunome (IMNM) Initiates Coverage with a Buy Rating by HC Wainw - GuruFocus
Immunome (IMNM): Biotech minnow in the spotlight as volatility returns to cancer drug hunters - AD HOC NEWS
Principal Financial Group Inc. Buys 762,147 Shares of Immunome, Inc. $IMNM - MarketBeat
Candriam S.C.A. Buys 541,441 Shares of Immunome, Inc. $IMNM - MarketBeat
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 5, 2026 - BioSpace
Immunome reports inducement grants under Nasdaq listing rule - marketscreener.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - BioSpace
Short Covering: Is Immunome Inc affected by consumer sentimentM&A Rumor & Consistent Profit Alerts - baoquankhu1.vn
Immunome stock hits 52-week high at $26.74 By Investing.com - Investing.com Canada
Immunome (NASDAQ:IMNM) Hits New 1-Year HighWhat's Next? - MarketBeat
Immunome stock hits 52-week high at $26.74 - Investing.com
Immunome, Inc. (NASDAQ:IMNM) Short Interest Down 12.6% in January - MarketBeat
The Insider Report: Batten Down the Hatches - Benzinga
Nan Fung Trinity HK Ltd. Has $6.93 Million Position in Immunome, Inc. $IMNM - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Can Immunome Inc. continue delivering strong returnsSwing Trade & Stepwise Trade Signal Guides - mfd.ru
Trading Recap: How do insiders feel about Immunome Inc2025 Earnings Impact & Free High Return Stock Watch Alerts - baoquankhu1.vn
Institutional Investors Are Immunome, Inc.'s (NASDAQ:IMNM) Biggest Bettors and Were Rewarded After Last Week's US$382m Market Cap Gain - 富途牛牛
Technical Analysis: Is TSHA part of any major indexTrade Analysis Report & Weekly Stock Performance Updates - baoquankhu1.vn
What are Immunome Incs recent SEC filings showingJuly 2025 Market Mood & Breakout Confirmation Trade Signals - baoquankhu1.vn
Immunome stock reaches 52-week high at $25.32 By Investing.com - Investing.com Australia
(IMNM) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Immunome (NASDAQ:IMNM) Hits New 12-Month HighWhat's Next? - MarketBeat
Immunome stock reaches 52-week high at $25.32 - Investing.com
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Teladoc (TDOC) and Immunome (IMNM) - The Globe and Mail
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunome Inc Stock (IMNM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barchas Isaac | Director |
Dec 22 '25 |
Sale |
21.74 |
383,200 |
8,330,080 |
2,031,181 |
| SIEGALL CLAY B | President and CEO |
Dec 19 '25 |
Buy |
20.48 |
7,278 |
149,053 |
860,525 |
| Tsai Philip | Chief Technical Officer |
Dec 19 '25 |
Buy |
20.49 |
10,000 |
204,900 |
43,300 |
| SIEGALL CLAY B | President and CEO |
Dec 18 '25 |
Buy |
21.50 |
46,511 |
999,986 |
853,247 |
| Higgins Jack | Chief Scientific Officer |
Sep 10 '25 |
Option Exercise |
1.35 |
22,000 |
29,700 |
40,729 |
| BIENAIME JEAN JACQUES | Director |
Jun 03 '25 |
Buy |
9.38 |
5,000 |
46,900 |
36,415 |
| Higgins Jack | Chief Scientific Officer |
Mar 27 '25 |
Option Exercise |
1.35 |
5,200 |
7,020 |
18,729 |
| BIENAIME JEAN JACQUES | Director |
Mar 25 '25 |
Buy |
7.78 |
7,800 |
60,684 |
31,415 |
| SIEGALL CLAY B | President and CEO |
Mar 26 '25 |
Buy |
7.29 |
137,100 |
999,459 |
806,736 |
| BIENAIME JEAN JACQUES | Director |
Mar 24 '25 |
Buy |
8.21 |
7,000 |
57,470 |
23,615 |
0.09%
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):